Skip to content

A pilot study of Behaviour Activation Therapy combined with ketamine treatment for people with treatment-resistant depression

COBAT Pilot: evaluation of the feasibility of implementation, acceptability, and preliminary marginal effectiveness of Co-adapted Behaviour Activation as an adjunct to ketamine for Treatment-resistant depression.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12626000475347
Enrollment
50
Registered
2026-04-16
Start date
2026-04-20
Completion date
2027-03-08
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

COBAT aims to help alleviate the chronic, severe disability experienced by people with treatment-resistant depression. Approximately 30% of people with depression don't respond to standard treatments. Ketamine has emerged as a novel treatment for this difficult-to-treat population, but approximately 50% don't respond and many relapse after ketamine treatment ends. This COBAT pilot is Phase 3 of broader COBAT study and aims to evaluate whether the co-adapted Behaviour Activation therapy manual can be feasibly delivered alongside ketamine treatment as a part of routine care, whether it is acceptable to patients, and whether it shows preliminary marginal effectiveness for future large-scale RCTs

Interventions

A co-produced behaviour activation therapy used as an adjunct to ketamine for treatment-resistant depression (BA-KET). The BA-KET intervention will be administered over an 8-week period by an AHPRA approved psychologist or supervised provisional psychologist, There are a total of 8-10 therapy sessions, alongside the current 8-week standard ketamine treatment protocols used at study sites. There are three components to the manualised BA-KET therapy: 1. The Therapist Manual 2. The Patient Manual

A co-produced behaviour activation therapy used as an adjunct to ketamine for treatment-resistant depression (BA-KET). The BA-KET intervention will be administered over an 8-week period by an AHPRA approved psychologist or supervised provisional psychologist, There are a total of 8-10 therapy sessions, alongside the current 8-week standard ketamine treatment protocols used at study sites. There are three components to the manualised BA-KET therapy: 1. The Therapist Manual 2. The Patient Manual 3. The Patient Journal/Workbook Within the BA-KET manual there are 7 core tasks or aims, which utilise 9 worksheets. The core tasks and aims include: Task 1: Notice – Understanding My Depression • Aim 1: Learn how depression works and how the participant’s behaviour affects their mood. Task 2: Track – Monitoring My Daily Life • Aim 2: Build awareness of what helps or hurts the participants mood. Task 3: Explore – Identifying My Values • Aim 3: Reconnect with what really matters to the participant. Task 4: Plan – Turning Values into Action • Aim 4: Take small, realistic steps that build momentum. Task 5: Connect – Strengthening My Relationships • Aim 5: Rebuild safe, supportive connections. Task 6: Grow – Consolidating My Progress • Aim 6: Recognise what’s working and build confidence. Task 7: Maintain – Planning for the Future • Aim 7: Prepare for ups and downs with a plan that keeps the participant safe and steady after discharge. The Therapist Manual is designed to provide therapists with enough information to help conduct sessions and guide patients through the core tasks of BA-KET. The Patient Manual provides a more user-friendly guide for participants to use to help remind them of what they are aiming to do with each task. It is designed to reduce patient burden, while giving them enough information to be useful. The Patient Workbook/Journal has empty versions of the worksheets which can be photocopied and revisited as they work through the tasks under the guidance of their therapist. Core components as described in the Therapist Manual: • BATAK-D is designed as an 8–10 session program, delivered in parallel with repeat-dose ketamine treatment. Each session typically lasts 45–60 minutes, with flexibility to adapt to the patient’s needs and clinical setting. Sessions are structured, with clear goals and worksheets, but the therapist is encouraged to adjust pacing and emphasis depending on patient progress, energy, and engagement. The lived-experience co-design team felt flexibility in the delivery time and method would help reduce the barriers to completing BA. The only consensus was that therapy would not do well during ketamine treatments. Obviously, there will be limitations within your service model and according to therapist schedules, so this conversation is best had prior to beginning treatment, in collaboration with patients. The first session must be conducted prior to beginning ketamine treatment whenever possible. We recommend the first two sessions be completed prior to beginning ketamine treatment to ensure adequate time to complete a formulation and practice activity monitoring. • Subsequent sessions are usually scheduled weekly and when possible, coordinated with patient preferences around ketamine dosing days. • We recommend you wait at least 4 hours after ketamine dosing, before a BA session. • We also recommend you avoid BA sessions immediately before ketamine treatments, to reduce cognitive load or potential psychosocial stressors prior to treatment. At least an hour break is recommended to allow the patient to process information and ground themselves prior to dosing with ketamine. • Otherwise, BA sessions may be conducted at any time around ketamine treatments. • Sessions are suitable to be conducted in-person or via teleconference. The Therapy Roadmap (and worksheets), as described in the Therapist Manual: Step 1 – Orientation & Preparation o Learn how ketamine and Behavioural Activation work together. Meet your therapist, learn about your depression, and prepare your journal. o Worksheet 1: depression formulation Step 2 – Monitoring My Days o Record what you do and how you feel. No judgment — just noticing patterns. o Worksheet 2: Activity monitoring Step 3 – Understanding My Cycles o Spot when avoidance keeps you stuck and when small actions help. o Worksheet 3: Vicious Cycles Step 4 – Exploring My Values o Identify what really matters to you across work, health, relationships, hobbies, and daily life. o Worksheet 4: Life Areas and Values Step 5 – Planning Activities o Turn your values into small, achievable actions. o Worksheet 5: Activity List Step 6 – Strengthening Connection o Map your support network and plan safe, meaningful contact with others. o Worksheet 6: My Connection Map o Worksheet 7: My Connection Activities Step 7 – Consolidating Progress o Review what’s worked, celebrate small wins, notice early warning signs. Step 8 – Planning for the Future o Create your Relapse Prevention Plan and gather your ongoing supports. o Worksheet 8: Relapse Awareness Checklist o Worksheet 9: Relapse Prevention Plan TREATMENT ADHERENCE - will be montired using the Behavioural Activation for Depression Scale long form (BADS-LF). KETAMINE TREATMENTS - Ketamine treatments are being conducted as per the standard treatment protocols at each site. - Ketamine treatments are not the intervention being investigated, and thus ketamine treatment algorithms are not being standardised, but rather are being used as per naturalistic protocols. - The dose, treatment frequency, and route of administration varies at each site, including esketamine nasal spray, subcutaneous ketamine injection, and intravenous ketamine infusion. - an 8-week program of ketamine treatments will be used. - All treatments are administered in clinics and thus, treatment adherence is assessed by attendance to scheduled treatment sessions.

Sponsors

The University of Sydney
Lead SponsorUniversity

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Adults with treatment resistant depression defined as inadequate response to at least two different antidepressants of adequate dose and duration in the current major depressive episode. Aged 18 years or over Assessed by clinic psychiatrist as eligible to receive clinical ketamine treatment, Assessed by clinic psychiatrist as eligible to receive Behavioural Activation Therapy Can attend Behavioural Activation Therapy sessions Depression score equal to or greater than 20 at commencement of treatment (using MADRS depression interview) Able to provide written informed consent for research study

Exclusion criteria

Unable to give informed consent, At high risk of harm to self or others, Unable to understand the intervention or complete clinic consent processes in English

Outcome results

None listed

Source: ANZCTR · Data processed: Apr 23, 2026